

S2 Table

Metric	PD-L1 Expression (IC group)	HR for Progression or Mortality	HR for Mortality
Intercept			
	IC0	(base group)	(base group)
	IC1	HR=0.29, 95% CI (0.079, 1.36)	HR=0.23, 95% CI (0.054, 1.10)
	IC2	HR=0.083, 95% CI (0.0087, 0.55)	HR=0.023, 95% CI (0.00047, 0.30)
Liver Metastasis			
	IC0	HR=4.17, 95% CI (0.53, 33.98)	HR=4.78, 95% CI (0.58, 53.10)
	IC1	HR=4.27, 95% CI (1.15, 15.08)	HR=4.11, 95% CI (0.91, 16.01)
	IC2	HR=3.80, 95% CI (0.79, 22.70)	HR=3.73, 95% CI (0.61, 24.52)
log(# Missense SNV / MB)			
	IC0	HR=1.00, 95% CI (0.49, 2.37)	HR=1.26, 95% CI (0.60, 3.19)
	IC1	HR=0.76, 95% CI (0.50, 1.16)	HR=0.83, 95% CI (0.50, 1.28)
	IC2	HR=0.53, 95% CI (0.33, 0.83)	HR=0.56, 95% CI (0.33, 1.00)
log(Pre-Treatment TCR Clonality)			
	IC0	HR=1.51, 95% CI (0.32, 7.22)	HR=1.08, 95% CI (0.21, 4.15)
	IC1	HR=1.09, 95% CI (0.32, 3.46)	HR=1.09, 95% CI (0.33, 3.81)
	IC2	HR=50.87, 95% CI (2.99, 1486.55)	HR=4895.08, 95% CI (80.81, 10374151.41)
log(TIL Proportion)			
	IC0	HR=0.12, 95% CI (0.0028, 3.46)	HR=0.053, 95% CI (0.00053, 11.87)
	IC1	HR=0.11, 95% CI (0.0077, 1.20)	HR=0.047, 95% CI (0.0018, 0.68)
	IC2	HR=0.078, 95% CI (0.0051, 1.07)	HR=0.026, 95% CI (0.00093, 0.40)

Summary of results from multivariate survival analysis of various clinical, peripheral and intratumoral factors to estimate their independent association with hazard for disease progression or mortality (PFS) and for mortality (OS) according to level of intratumoral PD-L1 expression (IC grade). Results are summarized as median and 95% posterior intervals.